loading
Summit Therapeutics Inc stock is traded at $27.75, with a volume of 2.18M. It is down -0.53% in the last 24 hours and up +59.87% over the past month. Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
See More
Previous Close:
$27.90
Open:
$27.9
24h Volume:
2.18M
Relative Volume:
0.58
Market Cap:
$17.91B
Revenue:
$956.00K
Net Income/Loss:
$-221.32M
P/E Ratio:
-86.71
EPS:
-0.32
Net Cash Flow:
$-142.25M
1W Performance:
+15.11%
1M Performance:
+59.87%
6M Performance:
+36.11%
1Y Performance:
+532.18%
1-Day Range:
Value
$26.71
$28.28
1-Week Range:
Value
$22.84
$29.99
52-Week Range:
Value
$2.10
$36.91

Summit Therapeutics Inc Stock (SMMT) Company Profile

Name
Name
Summit Therapeutics Inc
Name
Phone
305-203-2034
Name
Address
601 BRICKELL KEY DRIVE, MIAMI
Name
Employee
159
Name
Twitter
@summitplc
Name
Next Earnings Date
2025-02-24
Name
Latest SEC Filings
Name
SMMT's Discussions on Twitter

Compare SMMT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
SMMT
Summit Therapeutics Inc
27.73 17.91B 956.00K -221.32M -142.25M -0.32
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
500.09 127.64B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
604.05 65.95B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
655.78 37.92B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.27 32.98B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
255.39 26.89B 3.81B -644.79M -669.77M -6.24

Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-26-25 Upgrade Citigroup Neutral → Buy
Mar-21-25 Initiated Cantor Fitzgerald Overweight
Mar-12-25 Initiated Evercore ISI Outperform
Feb-28-25 Initiated Goldman Buy
Jan-08-25 Initiated Truist Buy
Dec-11-24 Initiated Wells Fargo Overweight
Dec-06-24 Initiated Jefferies Buy
Nov-04-24 Initiated JMP Securities Mkt Outperform
Sep-27-24 Downgrade Citigroup Buy → Neutral
Aug-12-24 Initiated H.C. Wainwright Buy
May-07-24 Initiated Citigroup Buy
Mar-26-24 Initiated Stifel Buy
Jun-28-18 Downgrade Janney Buy → Neutral
May-02-18 Initiated Janney Buy
Apr-12-18 Reiterated Needham Buy
Feb-13-18 Initiated BTIG Research Buy
Jan-04-18 Initiated SunTrust Buy
Dec-01-17 Resumed H.C. Wainwright Buy
Nov-16-16 Reiterated RBC Capital Mkts Outperform
Oct-05-16 Reiterated Needham Buy
Sep-16-16 Initiated H.C. Wainwright Buy
Mar-30-15 Initiated Needham Buy
Mar-30-15 Initiated Oppenheimer Outperform
View All

Summit Therapeutics Inc Stock (SMMT) Latest News

pulisher
May 04, 2025

Duolingo, CoreWeave And DexCom Are Among Top 10 Large-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio? - Benzinga

May 04, 2025
pulisher
May 04, 2025

Summit Therapeutics Q1 Loss Narrower Than Expected, Sales Nil - MSN

May 04, 2025
pulisher
May 04, 2025

Why Summit Therapeutics Inc. (SMMT) Soared Last Week - Insider Monkey

May 04, 2025
pulisher
May 04, 2025

These 10 Firms Soared Last Week, Here’s Why - Insider Monkey

May 04, 2025
pulisher
May 03, 2025

Summit Therapeutics outlines ivonescimab progress with key Phase III data expected mid-2025 - MSN

May 03, 2025
pulisher
May 02, 2025

Summit Therapeutics (SMMT) Stock: Goldman Sachs Raises Price Target | SMMT Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Summit Therapeutics: Promising Clinical Developments and Financial Stability Drive Buy Rating - TipRanks

May 02, 2025
pulisher
May 02, 2025

Decoding Summit Therapeutics Inc (SMMT): A Strategic SWOT Insigh - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2025 Earnings Call Transcript - Insider Monkey

May 02, 2025
pulisher
May 02, 2025

This Soaring Stock Just Delivered More Good News. Time to Buy? - The Globe and Mail

May 02, 2025
pulisher
May 02, 2025

Summit Therapeutics (SMMT) Advances with Ivonescimab in Key Tria - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Summit Therapeutics Reports Q1 2025 Progress and Financials - TipRanks

May 02, 2025
pulisher
May 02, 2025

Summit Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 02, 2025
pulisher
May 01, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

May 01, 2025
pulisher
May 01, 2025

Summit Therapeutics (SMMT) Beats Q1 Earnings Expectations - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Summit Therapeutics Inc Reports Q1 2025 EPS of $(0.09), Aligning with Estimates; Revenue Unreported - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Summit Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 01, 2025
pulisher
May 01, 2025

Summit Therapeutics Reports Financial Results and Operational Pr - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025 | SMMT Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025 - Business Wire

May 01, 2025
pulisher
May 01, 2025

Summit Therapeutics (SMMT) Sees Balanced Options Activity Ahead - GuruFocus

May 01, 2025
pulisher
Apr 30, 2025

Summit Therapeutics (SMMT) Earnings Report Expected Amidst Mixed Forecasts - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Summit Therapeutics (NasdaqGM:SMMT) Sees 16% Stock Price Increase Over Past Month - Yahoo Finance

Apr 30, 2025
pulisher
Apr 28, 2025

Why Is Summit Therapeutics Stock Trading Higher On Monday? - Benzinga

Apr 28, 2025
pulisher
Apr 28, 2025

Summit Therapeutics, Intel among Monday’s market cap stock movers By Investing.com - Investing.com South Africa

Apr 28, 2025
pulisher
Apr 28, 2025

Summit Therapeutics, Intel among Monday’s market cap stock movers - Investing.com

Apr 28, 2025
pulisher
Apr 28, 2025

Summit Therapeutics stock holds $44 target despite drop - Investing.com

Apr 28, 2025
pulisher
Apr 28, 2025

Summit Therapeutics stock holds $44 target despite drop By Investing.com - Investing.com India

Apr 28, 2025
pulisher
Apr 28, 2025

Summit Therapeutics stock holds $40 target at Citizens JMP By Investing.com - Investing.com Canada

Apr 28, 2025
pulisher
Apr 28, 2025

Summit Therapeutics stock holds $40 target at Citizens JMP - Investing.com

Apr 28, 2025
pulisher
Apr 28, 2025

Summit Therapeutics Shares Tumble Amid Trial Data Concerns - TipRanks

Apr 28, 2025
pulisher
Apr 28, 2025

Summit Therapeutics (SMMT) Maintains Buy Rating Despite Market O - GuruFocus

Apr 28, 2025
pulisher
Apr 28, 2025

Summit Therapeutics (SMMT) Maintains Buy Rating Despite Market Overreaction | SMMT Stock News - GuruFocus

Apr 28, 2025
pulisher
Apr 28, 2025

Why Summit Therapeutics Inc. (SMMT) Skyrocketed On Monday? - MSN

Apr 28, 2025
pulisher
Apr 27, 2025

Summit Therapeutics (SMMT) Shares Plummet After Survival Data Di - GuruFocus

Apr 27, 2025
pulisher
Apr 26, 2025

Akeso survival data for ivonescimab misses expectations, STAT says - Yahoo Finance

Apr 26, 2025
pulisher
Apr 26, 2025

Summit Therapeutics: New Ivonescimab Data Raise Concerns (NASDAQ:SMMT) - Seeking Alpha

Apr 26, 2025
pulisher
Apr 26, 2025

Summit Therapeutics Stock Plummets Amid Study Setback - Evrim Ağacı

Apr 26, 2025
pulisher
Apr 26, 2025

BioNTech And Summit Therapeutics Stocks Fluctuate Dramatically - Evrim Ağacı

Apr 26, 2025
pulisher
Apr 26, 2025

Summit Therapeutics (SMMT) Reports Ivonescimab's Approval in Chi - GuruFocus

Apr 26, 2025
pulisher
Apr 25, 2025

Summit Therapeutics (SMMT) Observes Notable Progress with Ivones - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Summit Therapeutics, Saia, And T-Mobile US Take A Hit In Trading - Finimize

Apr 25, 2025
pulisher
Apr 25, 2025

Akeso (AKESF) and Summit Therapeutics (SMMT) See Stock Declines After Drug Data Release | BNTX Stock News - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Summit Therapeutics Receives Buy Rating Amid Promising Ivonescimab Developments and Strategic Trials - TipRanks

Apr 25, 2025
pulisher
Apr 25, 2025

Merck (MRK) Reacts to Summit Therapeutics' Lung Cancer Therapy D - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Market Today: Alphabet's Earnings Boost Tech, Summit Therapeutics Plummets - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today - Mitrade

Apr 25, 2025
pulisher
Apr 25, 2025

Summit Therapeutics (SMMT) Price Target Raised Amid Positive Dru - GuruFocus

Apr 25, 2025

Summit Therapeutics Inc Stock (SMMT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$32.97
price up icon 0.05%
$21.58
price up icon 0.52%
$72.59
price up icon 0.52%
$101.00
price down icon 3.71%
biotechnology ONC
$255.47
price down icon 0.48%
Cap:     |  Volume (24h):